09:57 AM EST, 02/21/2025 (MT Newswires) -- Novo Nordisk ( NVO ) has resolved its shortage of weight-loss drugs Ozempic and Wegovy, according to a US Food and Drug Administration website update.

The resolved shortage issue means other companies will no longer be legally allowed to use copies of semaglutide, which is the generic name for the drugs.

Shares of Novo Nordisk ( NVO ) were up 3.9% in recent trading following the FDA's announcement, while shares of Hims & Hers Health (HIMS) were down 24%.

Price: 86.79, Change: +3.05, Percent Change: +3.64